Fluostar Optima plate reader ( ex = 485 nm,  em = 590 nm). The ratio was calculated as described in equation (1) ratio
where v is the product formation rate in the presence of inhibitor 7, seleginine and the absence of both, respectively. in case of stepwise dilutions, the enzyme concentration is reduced and thus the overall product formation is decelerated, the rates converge and the ratio value approaches 100%.
S9
Matriptase-2 assay. 6 Briefly, stably transfected human embryonic kidney (HEK) cells expressing matriptase-2 (MT-2) were cultivated, washed and the culture supernatant was collected, centrifuged and concentrated as described. Kinetic measurements were performed on a Fluostar Optima BMG Labtech plate reader in 96 well plates. MT-2 assay buffer (NaCl 150 mM, TRIS 50 mM, pH 8.0), Boc-Gln-Ala-Arg-AMC substrate in a final concentration of 40 µM and test compounds dissolved in DMSO were added.
The reaction with 10 µg of MT-2 supernatant to each well and followed over a time of 20 min at 37 °C ( ex = 340 nm,  em = 460 nm). S10 MAGL and CEase assays. Human MAGL was purchased from Cayman Chemical (MI, USA) as C-terminally hexahistidine-tagged protein expressed in Escherichia coli.
Human CEase was expressed and purified and the assays with MAGL and CEase were performed as reported. 7 -1-yl) 
6-(4-(Piperidin

6-(4-(4-Methylpiperazin-1-yl)butoxy)-4H-chromen-4-one (15)
was prepared following the general procedure B1. 6-((5-(4-Methylpiperazin-1-yl) Concd HCl (0.2 mL) was added and the resulting mixture was heated in a microwave apparatus at 50 °C for 1 h. After cooling, the mixture was partitioned between dichloromethane (10 mL) and 1M aqueous sodium bicarbonate solution (10 mL). The organic phase was isolated through a hydrophobic frit and concentrated to dryness, to give compound 27 (47.03 mg, 31%), MW 301.39. 1 
